PubRank

Deborah Defeo-Jones

Author PubWeight™ 18.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005 3.58
2 Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 2005 3.50
3 An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther 2010 1.77
4 Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett 2008 1.44
5 Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg Med Chem Lett 2005 1.27
6 Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorg Med Chem Lett 2007 0.98
7 Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate 2010 0.91
8 Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity. Bioorg Med Chem Lett 2008 0.86
9 Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors. Bioorg Med Chem Lett 2007 0.86
10 Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors. Bioorg Med Chem Lett 2008 0.81
11 Rapid assembly of diverse and potent allosteric Akt inhibitors. Bioorg Med Chem Lett 2007 0.80
12 Development of pyridopyrimidines as potent Akt1/2 inhibitors. Bioorg Med Chem Lett 2008 0.79
13 The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity. Bioorg Med Chem Lett 2008 0.79